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Abstract 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
levothyroxine improves exercise capacity in patients with thyroid disease.  
SUDY DESIGN: Review of three English language primary studies published in peer-reviewed 
journals in 2000, 2005, and 2009 
DATA SOURCES: Two randomized control trials and one clinical trial comparing 
leveothyroxine to euthryroid were found using Medline, and PubMed databases.  
OUTCOMES MEASURED: Each of the three studies measured heart rate and blood pressure 
before during, and after exercise in patients to determine the effect levothyroxine has on both 
heart rate and blood pressure 
RESULTS: One RCT found that submaximal cardiopulmonary exercise performance improved 
after six months of TSH normalization. The second RCT found that with careful tailoring of 
TSH-suppressive therapy there is improvement in exercise performance. The controlled clinical 
trial found that restoring a patient to normal TSH levels does not produce significant changes in 
substrate response to exercise.  
CONCLUSIONS: The results demonstrate that the studies do not agree on the effects of 
levothyroxine or euthyroid on exercise capacity.  
KEYWORDS: Hypothyroidism, exercise capacity, levothyroxine  
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INTRODUCTION 
Hypothyroidism is a condition in which the thyroid gland doesn’t produce enough thyroid 
hormone, where thyroid stimulating hormone (TSH) is greater than normal, and the thyroid 
hormone (T4) levels are decreased. Thyroid hormones stimulate metabolic activities in most 
bodily tissues and when levels decrease, metabolism slows.1 Major targets for thyroid hormones 
are the heart and skeletal muscle. Therefore, hypothyroidism can lead to weaker heart muscle, 
causing decreased cardiac output and contractility, bradycardia, and an increase in vascular 
resistance.2 This can ultimately lead to a negative impact on an individual’s quality of life.  
It is estimated that 10 million Americans (approximately 1% of the US population) are 
diagnosed with hypothyroidism.1,3 Higher rates of hypothyroidism have been diagnosed in 
women and in individuals over the age of 50.1 Although the annual cost or number of healthcare 
visits is not available for the US, in Germany, data shows that iodine-deficiency hypothyroidism 
costs approximately 1 billion dollars annually and inpatient care accounts for nearly $250 million 
a year.4   
There are several different causes of hypothyroidism. Iodine deficiency is the most 
common cause of hypothyroidism worldwide. The most common form found in the US is 
Autoimmune thyroiditis (Hashimoto’s disease), which can be associated with a goiter and results 
in gradual loss of thyroid function. Hashimoto’s disease has a mean incidence of 4/1,000F and 
1/1,000M. Congenital hypothyroidism is caused by thyroid gland dysgenesis, is present in 
1/4,000 newborns and can either be transient or permanent.1 
Thyroid hormone is produced in the thyroid gland using iodine. Thyroxine (T4) and 
triiodothyronine (T3) are the two most important hormones. In the blood, all hormones are 
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converted into T3, the active hormone that affects the metabolism of cells. Since hypothyroidism 
can affect many different body systems, many individuals seek medical care due to the effects of 
hypothyroidism before they are even diagnosed. Individuals will often experience: fatigue, 
lethargy, anorexia, constipation, depression, menstrual changes, muscle stiffness, cold 
intolerance, dry skin, memory impairment. Definitive treatment for individuals with 
hypothyroidism is through the use of daily medication. Standard treatment is Levothyroxine 
(Synthroid), a form of T4. The dosage of levothyroxine is based between1.0-1.7 mcg/kg/day. 
Second line treatments include: Cytomel (Liothyronine), a form T3, and Armour thyroid, a 
T3/T4 combination.1 Since hypothyroidism affects metabolism, it consequently affects skeletal 
muscle, cardiac function, and exercise capacity (maximal physical exertion) in individuals. When 
taking levothyroxine, the T4 hormone that is naturally produced in the body is replaced. This 
allows the body to function with normal hormone levels, ultimately decreasing the physical, 
cardiac and vascular effects of hypothyroidism within the body. In the three reviewed studies, 
decreased exercise capacity is evaluated through heart rate (HR) and blood pressure (BP), along 
with other factors. Being the standard treatment for hypothyroidism, levothyroxine may provide 
positive outcomes in regards to exercise capacity by helping to reverse the negative effects 
triggered by low thyroid hormone.  
OBJECTIVE 
The objective of this systematic review is to determine if levothyroxine is effective in 
increasing exercise capacity in subjects with thyroid disease. 
METHODS 
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Studies for this systemic review were found using the key words: hypothyroidism, 
exercise capacity and levothyroxine. All studies were published in peer-reviewed journals in 
English. All literature searches were performed through Medline and PubMed. Inclusion criteria 
for the review were: POEM, randomized controlled trials and studies that were posted in 1996 or 
later. Exclusion criteria for the review included: drugs that could influence heart rate, blood 
pressure or thyroid function, except levothyroxine. The statistics used in the reviewed studies 
includes P-values, ANOVA, T-test, and Wilcoxon test.  
Three studies (2 RCT, 1 clinical trial) were selected for this review and met the following 
criterion:1) The population of participants included male and/or female subjects receiving 
levothyroxine for thyroid disease; 2) Interventions used were levothyroxine either in a fixed dose 
or dosed to make an individual euthyroid; 3) Comparison groups in the study were euthyroid 
subjects compared to those taking levothyroxine and 4) Outcomes measured were blood pressure 
and/or heart rate. A summary of the design and results of the three studies is outlined in Table 1.  
 The study performed by Mainenti et al. was conducted in Rio de Janeiro, Brazil at the 
Federal University of Rio de Janeiro. Subjects were recruited from the outpatient Endocrine 
Clinic at the University. Inclusion criteria for the study included: untreated 30-60 years old with 
increased TSH >4.0 and Normal free T4 levels. Exclusion criteria used for the study were: 
subjects taking drugs that alter thyroid function, HR and/or BP, an individual diagnosed with 
cardiac diseases including atrial hypertension, and lastly problems that could interfere with 
walking. All subjects met the inclusion and exclusion criteria of the study and gave written 
consent that was approved by the ethics committee.5  
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The study performed by Caraccio et al. was conducted in Pisa, Italy at the University of 
Pisa School of Medicine. Individuals, aged 26-34, were recruited from the outpatient clinic with 
elevated TSH levels (>3.6 mlU/liter) and Hashimoto’s thyroiditis which was verified with 
positive antithyroid peroxidase and antithyroid autoantibody titers. Exclusion criterion included: 
any parameters found outside of the given inclusion criteria for sex, age, BMI, body composition 
and subjects without Hashimoto’s thyroiditis. Subjects had blood sampled and were evaluated 
for neurologic, cardiovascular, respiratory or other systemic diseases.  The study protocol was 
approved by the ethics committee and all subjects signed and confirmed informed consent.6  
The study performed by Mercuro et al. took place at the University of Cagliari in 
Cagliari, Italy. The inclusion criteria for this study included: individuals 26-65 years old, long 
term TSH-suppressive fixed dose levothyroxine therapy of 700-1575mcg for 2-20 years, a 
normal free T3 and suppressed TSH < 0.1 mU/L. Exclusion criteria includes: subjects taking 
drugs for cardiovascular disease or any medications other than levothyroxine. All of the subjects 
were screened for cardiovascular disease or the concomitant use of other medications.7  
Table 1: Demographics of included studies 
 
Study Design Subjects Age Inclusion 
criteria 
Exclusion 
criteria 
W/D Interventions 
Mainenti 
et al.5; 
2009 
RCT 23 30-60 Untreated 
subjects; 30-
60 yo; 
increased 
TSH >4.0, 
Normal free 
T4 levels 
Drugs that 
could change 
thyroid fx, 
HR, BP; 
diagnosed 
cardiac ds, 
atrial HTN; 
problems that 
can interfere 
with walking 
N/A TSH 
normalized 
with 
levothyroxine 
Caraccio 
et al.6; 
2005 
RCT 33 26-34 Increased 
TSH >3.6, 
normal free 
Subjects that 
don’t match 
control group 
N/A 12mo 
levothyroxine 
replacement 
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T3&4 levels; 
+ 
Hashimoto’s 
thyroiditis, + 
antithyroid 
peroxidase 
& 
antithyroid 
autoantibody 
titers  
for sex, age, 
BMI, body 
composition; 
Pts with 
negative ds or 
antithyroid 
titers  
to euthyroid  
Mercuro 
et al.7; 
2000 
Clinical 
Trial 
38 26-65 Long term 
therapy of 
700-
1575mcg X 
2-20 years; 
normal free 
T3; 
suppressed 
TSH <  0.1 
mU/L 
Cardiovascular 
ds; taking any 
drugs other 
than 
levothyroxine; 
No 
sympatholytic 
meds X 1yr  
N/A Levothyroxine 
at fixed dose 
of 1.8-4 
mcg/kg 
 
OUTCOMES MEASURED 
The primary outcomes measured in the studies were HR and/or BP. The values were 
measured before, during, and after exercise in subjects to determine the effect that levothyroxine 
has on both HR and BP. In each of the three studies, subjects were monitored using an EKG 
during exercise from which they could determine the HR. In the Mainenti et al. study the BP was 
measured using the ausculatroy method before exercise and at three minute intervals during 
exercise.5 In the Mercuro et al. study arterial BP was measured every three minutes of exercise 
and at the first, fifth and tenth minute of recovery using a mercury sphygmomanometer.7 
Although the studies measured HR and/or BP, the studies also looked at other 
measurements. Mainenti et al. measured HR, oxygen uptake, minute ventilation and other 
cardiopulmonary parameters within the fifth minute of exercise to obtain sub-maximal exercise 
measurements.5 Caraccio et al. measured HR, oxygen uptake (VO2), and carbon dioxide output  
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during an incremental aerobic exercise test. At rest, every two minutes during the incremental 
aerobic exercise test, and during twenty minutes of recovery blood “glucose, lactate, pyruvate, 
free fatty acid, glycerol and B-hydroxybutyrate concentrations” were measured.6 Mercuro et al. 
evaluated cardiac function through clinical, echocardiogram and ergometabolic means. The 
evaluation includes “intraventricular septum thickness, left ventricular posterior wall thickness, 
end-diastolic dimension and left ventricular mass index”. “During the exercise portion of the 
study exercise tolerance (maximal tolerated workload), maximal VO2, and anaerobic threshold” 
was evaluated in addition to heart rate.7  
RESULTS 
The results from the reviewed studies were presented as continuous data, which cannot be 
changed to data in the dichotomous form. Studies looked at HR and/or BP to help determine the 
effects that levothyroxine has on exercise metabolism by comparing control to treated subjects. 
Studies compared BP and/or HR at base line and then again at six months along with monitoring 
the values during exercise. With lower HR values during exercise the heart is working more 
efficiently and pumping more blood through the body with each beat. This means that at the 
same level of exercise, with a lower HR one is working less hard and pumping more blood to the 
tissues and organs in the body.8 The same concept is used with BP during exercise. Blood 
pressure is a reflection of the resistance of blood flow through the arteries. If your BP is lower 
during exercise, the heart is working less to pump blood throughout the body. A lower HR and 
BP during exercise helps the body work more efficiently. With an elevated HR or BP during 
exercise one may experience: decreased ability to perform exercise routines, chest pain, 
palpitations, increased shortness of breath, increased fatigue, and headache.   
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Mainenti et al. reported HR of untreated subjects of 129 + 17 bpm at baseline and 128 + 
17 bpm at six months vs 128 +17 bpm at baseline and 121 + 17 bpm at six month follow up for 
treated subjects. The p-value for HR was statistically significant with p<0.05. When compared 
before and at peak exercise, both systolic and diastolic blood pressure values were not 
significantly different from baseline to the six month follow-up. Systolic blood pressure (SBP) in 
untreated subjects at baseline was 142.7 + 26.8 mmHg and 154.55 + 23.9 mmHg at six months. 
For the treated subjects SBP was 145.5 +17.9 mmHg and 142.3 + 18.2 mmHg, respectfully. Prior 
to exercise, the mean BP was “116/79 mmHg vs 120/81 mmHg (untreated) and 122/80 mmHg vs 
119/80 mmHg (treated)”. At peak exercise, mean BP values were “159/90 mmHg vs 173/89 
mmHg (untreated) and 158/87 mmHg vs 154/86 mmHg (treated)”.5 A summary of the results 
can be found in table 2.   
Table 2: Summary of BP and HR as outline in the Mainenti et al. 
Study5   
  Untreated  Subjects Treated  Subjects 
 (n = 12)   (n = 11)   
  Baseline 6 months Baseline 6 months 
     
HR (bpm) 129 + 17  128 + 17  128 +17  121 + 17  
SBP (mmHg) 142.7 + 26.8 154.55 + 23.9 145.5 +17.9  142.3 + 18.2  
BP mean 116/79 120/81  122/80 119/80  
(prior to exercise)         
BP mean 159/90  173/89  158/87  154/86  
(at peak exertion)         
The p-value was statistically significant with <0.05   
 
Caraccio et al. reported that euthyroid subjects experienced a higher HR as the workload 
increased compared to their control counterparts. This data was found to be statistically 
significant with P<0.03. Resting HR in untreated subjects was 85 + 3 bpm vs 78 + 4 bpm for 
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control subjects ( (table 3). Following twenty minutes of exercise, the subjects HR was about 170 
bpm vs 145 bpm for the control group. Resting HR in treated subjects was 78 + 3 bpm (baseline) 
vs 79 + 3 bpm (six months), whereas HR in placebo subjects was 85 + 2 bpm vs 89 + 3 bpm 
respectfully.6 In follow up studies, there were no substantial differences observed between the 
placebo and active treatment for HR values.  
Table 3: Summary of gathered HR data  in the 
Caraccio et al. study6 
 Untreated Control 
   Subjects  Subjects 
Resting HR (bpm) 85 + 3 78 + 4 
Exercise HR (min 10) ~145 ~130 
Exercise HR (min 20) ~170 ~145 
Data was significant with P<0.03  
 
Mercuro et al. reported a slightly higher HR in the experimental group compared to the 
control group, with p<0.01. Resting HR was 88 + 17 bpm in subjects vs 88 + 8 bpm in the 
control group. At peak exercise, HR was 96 + 6.9 bpm and 95 + 2 bpm respectfully. SBP was 
133 + 25 bpm and 114 + 10 bpm respectfully and 183 + 18 bpm and 179 + 14 bpm respectfully. 
In regards to BP, P<0.05.7 This data is represented in table 4.  
 
 
 
 
 
 
 
Table 4: Mercuro et al. table of results summary7  
 
Treated  
Subjects 
Control  
Subjects 
  (n=9) (n=9) 
Resting HR (bpm) 88 + 7  88 + 8  
Peak Exercise HR 96 + 6.9  95 + 2  
Resting SBP  (mmHg) 133 + 35  114 + 10  
Peak SBP ( mmHg) 183 + 18  179 + 14  
p<0.01   
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Mainenti et al. trial looked at treated and untreated experimental groups compared the 
results between baseline and six month follow up.5 The Caraccio et al. trial studied treated 
subjects vs placebo both at baseline and then six month after treatment.6 Finally, the Mercuro et 
al. study compared the experimental group and then the control group.7 All three studies were 
without adverse affects, and therefore numbers needed to harm could not be calculated.  
During all three studies, subjects were monitored at baseline and then at the six month 
follow-up and all parameters were measured at several intervals during exercise. None of the 
studies reported any loss of participants or adverse effects during the study causing subjects to 
leave.  
DISCUSSION 
Hypothyroidism is a very common endocrine disorder, especially in older women. 
Thyroid hormone released from the thyroid gland works to control the metabolism in the body. 
When levels are low, all functions of metabolism are decreased. Levothyroixine is the treatment 
of choice for hypothyroidism since it replaces T4, which is then converted into T3, the active 
from of thyroid hormone.1 Since thyroid hormone is used to directly replace the hormone that is 
absent in the body, it is thought that all effects of the metabolic disorder will be reversed.  
The studies used participants that were being seen and some treated for sub-clinical 
hypothyroidism. The participants of the studies were not on any other medication or had any 
other physical ailments that would prohibit them from performing the exercise portion of the 
study. All placebo or controlled subjects were matched for age, sex, BMI, and body composition. 
The studies took baseline and six month follow-up measurements. In the three studies, blinding 
did not seem to be compromised.  
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The Mainenti et al. study showed that in subjects who had received levothyroxine 
treatment had a decrease in HR after the six months. In the same treated group, the study found 
that at peak exercise exertion, BP was lower than in the untreated group. With these results, it 
was shown that at submaximal exercise, treated subjects spent less energy than the untreated 
group.5  
Caraccio et al. demonstrates that untreated subjects show increased HR levels when 
compared to euthyroid subjects at an equal exercise intensity. The study was not able to find 
significant changes in energy or response to exercise. Levothyroxine did not appear to correct the 
exercise impairment found in sub-clinical hypothyroidism during the course of the study.6   
Mercuro et al. was able to show that HR in subjects was slightly higher than euthyroid 
individuals during exercise, but “careful adjustment of levothyroxine dose can reverse and 
almost completely normalize cardiopulmonary” function.7  
CONCLUSIONS 
Two of the three studies show that there is a statistical difference in exercise capacity 
between untreated and treated subjects and between baseline and the six month follow up. Since 
there is discrepancy between the three studies, it cannot be stated that there is added benefit, for 
exercise capacity, to treatment in those with subclinical hypothyroidism. Therefore, the evidence 
is equivocal in determining a conclusive answer to whether or not levothyroxine is effective in 
increasing exercise capacity in subjects with thyroid disease.  
Even though there are many individuals diagnosed with hypothyroidism yearly, it is a 
health disparity that requires further attention. Since subjects are given T4 in the form of 
levothyroxine to treat their hypothyroidism, each subject could respond differently to the 
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treatment, causing discrepancy in the study result. Instead of having a set TSH level in future 
studies, it might be beneficial to titrate levothyroxine to symptomatic treatment and then perform 
exercise studies. This would increase the chance that each individual person would be receiving 
the correct amount of treatment for their body and not being based just on lab values.  
If a study could be conducted on populations at high risk for the development of sub-
clinical hypothyroidism before being diagnosed or treated, it might help determine if those who 
are more active in their youth have a higher probability of responding to medicine and, thus, be 
able to reverse the effects of hypothyroidism on the body.   
Researchers may also consider whether Synthroid, the brand name of levothyroxine, 
affects subjects significantly different compared to the generic form. If this is the case, then one 
form could be prescribed more in situations where exercise capacity is decreased.  
Since each of the three reviewed studies had a small subject population, it would be 
beneficial to gather a larger subject population to help provide more conclusive data in the 
future. Apart of the subject population for the studies should be a placebo group to help compare 
results. This was not done in the Mainenti et al. study.  
In conclusion, long term and larger subject trials are needed to help determine if 
levothyroxine does have a positive benefit on exercise tolerance in those with hypothyroidism 
since the three reviewed studies in this case review yielded inconclusive results.  
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